Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs [PDF]
Parasites & Vectors, 2015 Background Fluralaner is a novel systemic ectoparasiticide for dogs providing immediate and persistent flea, tick and mite control after a single oral dose.
Feli M. Walther +2 more
doaj +3 more sources
Comparative efficacy of oral administrated afoxolaner (NexGard™) and fluralaner (Bravecto™) with topically applied permethrin/imidacloprid (Advantix(®)) against transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs. [PDF]
Parasit Vectors, 2016 BACKGROUND : The ability of the topical spot-on Advantix® (50 % permethrin/10 % imidacloprid) to prevent transmission of Ehrlichia canis by infected Rhipicephalus sanguineus ticks to dogs has previously been reported.
Jongejan F +4 more
europepmc +2 more sources
Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime - praziquantel [PDF]
Parasites & Vectors, 2014 Background Fluralaner (Bravecto™; Merck/MSD Animal Health) is a novel systemic ectoparasiticide for dogs providing long-acting flea and tick control after a single oral dose.
Feli M Walther +4 more
doaj +2 more sources
Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs [PDF]
Parasites & Vectors, 2014 Background Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight.
Janina Taenzler +6 more
doaj +2 more sources
The speed of kill of fluralaner (Bravecto™) against Ixodes ricinus ticks on dogs [PDF]
Parasites & Vectors, 2014 Background Pathogens that are transmitted by ticks to dogs, such as Anaplasma phagocytophilum, Babesia spp., Borrelia burgdorferi sensu latu, and Ehrlichia canis, are an increasing problem in the world. One method to prevent pathogen transmission to dogs
Christina Wengenmayer +6 more
doaj +2 more sources
Prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs treated orally with fluralaner chewable tablets (Bravecto™) [PDF]
Parasites & Vectors, 2015 Background The preventive effect of fluralaner chewable tablets (Bravecto™) against transmission of Babesia canis by Dermacentor reticulatus ticks was evaluated. Methods Sixteen dogs, tested negative for B.
Janina Taenzler +3 more
doaj +2 more sources
A randomized controlled trial of the efficacy of orally administered fluralaner (Bravecto™) against induced Ixodes holocyclus (Australian paralysis tick) infestations on dogs [PDF]
Parasites & Vectors, 2015 Background Ixodes holocyclus ticks are a frequently fatal threat to dogs in eastern Australia. These ticks secrete a neurotoxin that can produce an ascending paralysis after 72 h attachment that can lead to death in affected animals.
Petr Fisara, Maurice Webster
doaj +2 more sources
Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in a simulated home environment [PDF]
Parasites & Vectors, 2014 Background Fluralaner, a novel isoxazoline, has both acaricidal and insecticidal activity through potent blockage of GABA- and L-glutamate-gated chloride channels.
Heike Williams +4 more
doaj +2 more sources
Quantifying the performance of a top-down natural ventilation Windcatcher™ [PDF]
, 2009 Estimating the performance of a natural ventilation system is very important if one is to correctly size the system for a particular application. Estimating the performance of a Windcatcher™ is complicated by the complex flow patterns that occur during ...
Kirby, R, Jones, BM
core +7 more sources
Comparative efficacy of two oral treatments for dogs containing either afoxolaner or fluralaner against Rhipicephalus sanguineus sensu lato and Dermacentor reticulatus [PDF]
, 2015 The present study compares the efficacy of two recent oral ectoparasiticides containing isoxazolines (NexGard®, containing afoxolaner and administered at a monthly regimen, and Bravecto™ containing fluralaner and administered at a tri-monthly regimen ...
Beugnet, Frederic +2 more
core +1 more source